Behavioural assays to model cognitive and affective dimensions of depression and anxiety in rats

Journal of Neuroendocrinology

Volumn 20, Issue 10, 2008, Pages 1115-1137

  Lapiz Bluhm, M D S ^a   Bondi, C O ^a   Doyen, J ^a   Rodriguez, G A ^a   Bedard Arana T ^a   Morilak, David A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Aattentional set shifting; Anxiety; Defensive burying; Depression; Elevated plus maze; Social interaction

Indexed keywords

ANTIDEPRESSANT AGENT;

AFFECT; ANXIETY; ANXIETY DISORDER; COGNITION; DEPRESSION; DISEASE ASSOCIATION; EXPERIMENTAL ANIMAL; LONG TERM CARE; MAZE TEST; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; REVIEW; STRESS; SYMPTOM;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; COGNITION DISORDERS; DEPRESSION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MOOD DISORDERS; NEUROPSYCHOLOGICAL TESTS; RATS; RATS, INBRED STRAINS; REPRODUCIBILITY OF RESULTS;

EID: 51449099594     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2008.01772.x     Document Type: Review

References (147)

1. Duyk G. Attrition and translation. Science 2003; 302:603-605.
2. Enserink M. Can the placebo be the cure ? Science 1999; 284:238-240.
3. Matthews K, Christmas D, Swan J, Sorrell E. Animal models of depression: navigating through the clinical fog. Neurosci Biobehav Rev 2005; 29 503-513.
4. McArthur R, Borsini F. Animal models of depression in drug discovery: A historical perspective. Pharmacol Biochem Behav 2006; 84:436-452.
5. Winsky L, Brady L. Perspective on the status of preclinical models for psychiatric disorders. Drug Discov Today Dis Models 2005; 2:279-283.
6. Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: A dimensional approach to understanding their behavioral effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2004;7:193-218.
7. Mineka S, Watson D, Clark LA. Comorbidity of anxiety and unipolar mood disorders. Annu Rev Psychol 1998; 49:377-412.
8. Beck AT. Cognitive Therapy and the Emotional Disorders. New York, NY: International Universities Press, 1976.
9. Beck AT, Brown G, Steer RA, Eidelson JI, Riskind JH. Differentiating anxiety and depression: A test of the cognitive content-specificity hypothesis. J Abnorm Psychol 1987; 96:179 -183.
10. Coles ME, Heimberg RG. Memory biases in the anxiety disorders: Current status. Clin Psychol Rev 2002; 22:587-627.
11. Mathews A, Mackintosh B. A cognitive model of selective processing in anxiety. Cognit Ther Res 1998; 22:539-560.
12. MacLeod C, Hagan R. Individual differences in the selective processing of threatening information, and emotional responses to a stressful life event. Behav Res Ther 1992; 30:151-161.
13. Anisman H, Matheson K. Stress, depression, and anhedonia: Caveats concerning animal models. Neurosci Biobehav Rev 2005; 29:525-546.
14. Fossati P, Amar G, Raoux N, Ergis AM, Allilaire JF. Executive functioning and verbal memory in young patients with unipolar depression and schizophrenia. Psychiatry Res 1999; 89:171-187.
15. Murphy FC, Sahakian BJ, Rubinsztein JS, Michael A, Rogers RD, Robbins TW, Paykel ES. Emotional bias and inhibitory control processes in mania and depression. Psychol Med 1999; 29:1307-1321.
16. Austin M-P, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001; 178:200-206.
17. Merriam EP, Thase ME, Haas GL, Keshavan MS, Sweeney JA. Prefrontal cortical dysfunction in depression determined by Wisconsin Card Sorting Test performance. Am J Psychiatry 1999; 156:780-782.
18. Murphy FC, Michael A, Robbins TW, Sahakian BJ. Neuropsychological impairments in patients with major depressive disorder: The effects of feedback on task performance. Psychol Med 2003; 33: 455-467.
19. Davidson RJ, Pizzagallli D, Nitschke JB, Putnam K. Depression: perspectives from affective neuroscience. Annu Rev Psychol 2002; 53:545-574.
20. Rogers MA, Kasai K, Koji M, Fukuda R, Iwanami A, Nakagome K, Fukuda M, Kato N. Executive and prefrontal dysfunction in unipolar depression: A review of neuropsychological and imaging evidence. Neurosci Res 2004; 50:1-11.
21. Sheline YI. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 2003; 54:338-352.
22. Goldstein G, Minshew NJ, Allen DN, Seaton BE. High-functioning autism and schizophrenia: A comparison of an early and late onset neurodevelopmental disorder. Arch Clin Neuropsychol 2002; 17:461-475.
23. Birrell JM, Brown VJ. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 2000; 20:4320-4324.
24. Dias R, Robbins TW, Roberts AC. Primate analogue of the Wisconsin Card Sorting Test: Effects of excitotoxic lesions of the prefrontal cortex of the marmoset. Behav Neurosci 1996; 110:872-886.
25. Dias R, Robbins TW, Roberts AC. Dissociable forms of inhibitory control within prefrontal cortex with an analog of the Wisconsin Card Sort Test: restriction to novel situations and independence from 'on-line' processing. J Neurosci 1997; 17:9285-9297.
26. Owen AM, Roberts AC, Polkey CE, Sahakian BJ, Robbins TW. Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalohippocampectomy. Neuropsychologia 1991; 29:993-1006.
27. Morgan MA, Schulkin J, LeDoux JE. Ventral medial prefrontal cortex and emotional perseveration: The memory for prior extinction training. Behav Brain Res 2003; 146:121-130.
28. Brown VJ, Bowman EM. Rodent models of prefrontal cortical function. Trends Neurosci 2002; 25:340-343.
29. McAlonan K, Brown VJ. Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. Behav Brain Res 2003; 146:97-103.
30. Tollefson GD. Cognitive function in schizophrenic patients. J Clin Psychiatry 1996; 57: 31-39.
31. Roberts AC, Robbins TW, Everitt BJ, Muir JL. A specific form of cognitive rigidity following excitotoxic lesions of the basal forebrain in marmosets. Neuroscience 1992; 47:251-264.
32. Aston-Jones G, Rajkowski J, Cohen J. Locus coeruleus and regulation of behavioral flexibility and attention. Prog Brain Res 2000; 126:165-182.
33. Lapiz MDS, Morilak DA. Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 2006; 137:1039-1049.
34. Lapiz MDS, Bondi CO, Morilak DA. Chronic treatment with desipramine improves cognitive performance of rats in an attentional set shifting test. Neuropsychopharmacology 2007; 32:1000-1010.
35. Bondi CO, Rodriguez G, Gould GG, Frazer A, Morilak DA. Chronic unpredictable stress induces a cognitive deficit and anxiety-like behavior in rats that is prevented by chronic antidepressant drug treatment. Neuropsychopharmacology 2008; 33:320-331.
36. Morilak DA, Lapiz-Bluhm MD. Chronic intermittent cold stress induces impairment in reversal learning in the rat on an attentional set-shifting task. Soc Neurosci Abstr 2007; 33, Online: Program number 643.14.
37. Lovic V, Fleming AS. Artificially-reared female rats show reduced prepulse inhibition and deficits in the attentional set shifting task: reversal of effects with maternal-like licking stimulation. Behav Brain Res 2004; 148:209-219.
38. Stuss DT, Levine B, Alexander MP, Hong J, Palumbo C, Hamer L, Murphy KJ, Izukawa D. Wisconsin Card Sorting Test performance in patients with focal frontal and posterior brain damage: Effects of lesion location and test structure on separable cognitive processes. Neuropsychologia 2000; 38:388-402.
39. Chen KC, Baxter MG, Rodefer JS. Central blockade of muscarinic cholinergic receptors disrupts affective and attentional set-shifting. Eur J Neurosci 2004; 20:1081-1088.
40. Tait DS, Brown VJ. Lesions of the basal forebrain impair reversal learning but not shifting of attentional set in rats. Behav Brain Res 2008; 187:100-108.
41. Tait DS, Brown VJ. Difficulty overcoming learned non-reward during reversal learning in rats with ibotenic acid lesions of orbital prefrontal cortex. Ann NY Acad Sci 2007; 1121:407-420.
42. Barense MD, Fox MT, Baxter MG. Aged rats are impaired on an attentional set-shifting task sensitive to medial frontal cortex damage in young rats. Learn Mem 2002; 9:191-201.
43. Fox MT, Barense MD, Baxter MG. Perceptual attentional set-shifting is impaired in rats with neurotoxic lesions of posterior parietal cortex. J Neurosci 2003; 23:676-681.
44. Hatcher PD, Brown VJ, Tait DS, Bate S, Overend P, Hagan JJ, Jones DNC. 5-HT 6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology 2005; 181:253-259.
45. Redei E, Pare WP, Aird F, Kluczynski J. Strain differences in hypothalamic-pituitary-adrenal activity and stress ulcer. Am J Physiol 1994; 266:R353-R360.
46. Pardon M-C, Gould GG, Garcia A, Phillips L, Cook MC, Miller SA, Mason PA, Morilak DA. Stress reactivity of the brain noradrenergic system in three rat strains differing in their neuroendocrine and behavioral responses to stress: Implications for susceptibility to stress-related neuropsychiatric disorders. Neuroscience 2002; 115:229-242.
47. Pare WP. Open field, learned helplessness, conditioned defensive burying, and forced-swim tests in WKY rats. Physiol Behav 1994; 55:433-439.
48. Colacicco G, Welzl H, Lipp H-P, Wurbel H. Attentional set-shifting in mice: Modification of a rat paradigm, and evidence for strain-dependent variation. Behav Brain Res 2002; 132:95-102.
49. Garner JP, Thogerson CM, Wurbel H, Murray JD, Mench JA. Animal neuropsychology: Validation of the intra-dimensional extra-dimensional set shifting task for mice. Behav Brain Res 2006; 173:53-61.
50. DeSteno DA, Schmauss C. Induction of early growth response gene 2 expression in the forebrain of mice performing an attention-set-shifting task. Neuroscience 2008; 152:417-428.
51. Cecchi M, Khoshbouei H, Javors M, Morilak DA. Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuroscience 2002; 112:13-21.
52. Cecchi M, Khoshbouei H, Morilak DA. Modulatory effects of norepinephrine, acting on α 1 -receptors in the central nucleus of the amygdala, on behavioral and neuroendocrine responses to acute immobilization stress. Neuropharmacology 2002; 43:1139-1147.
53. Khoshbouei H, Cecchi M, Dove S, Javors M, Morilak DA. Behavioral reactivity to stress: Amplification of stress-induced noradrenergic activation elicits a galanin-mediated anxiolytic effect in central amygdala. Pharmacol Biochem Behav 2002; 71:407-417.
54. Khoshbouei H, Cecchi M, Morilak DA. Modulatory effects of galanin in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuropsychopharmacology 2002; 27:25-34.
55. Montgomery KC. The relation between fear induced by novel-stimulation and exploratory behavior. J Comp Physiol Psychol 1958; 48: 254-260.
56. Handley SL, Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn-Schmiedeberg's Arch Pharmacol 1984; 327:1-5.
57. Pellow S, Chopin P, File SE, Briley M. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985; 14:149-167.
58. Lister RG. Ethologically-based animal models of anxiety disorders. Pharmacol Ther 1990; 46:321-340.
59. Handley SL, McBlane JW. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J Pharmacol Toxicol Methods 1993; 29:129-138.
60. File SE, Lippa AS, Beer B, Lippa MT. Animal tests of anxiety. In: Crawley JN, Gerfen CR, Rogawski MA, Sibley DR, Skolnick P, Wray S, eds. Current Protocols in Neuroscience. New York, NY: John Wiley & Sons, 2000: 8.3.1-8.3.19.
61. File SE. Factors controlling measures of anxiety and responses to novelty in the mouse. Behav Brain Res 2001; 125:151-157.
62. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987; 92: 180-185.
63. Rodgers RJ, Cole JC, Aboualfa K, Stephenson LH. Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol Biochem Behav 1995; 52: 805-813.
64. Rodgers RJ, Johnson NJT. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav 1995; 52:297-303.
65. Shepard JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Behavioural and pharmacological characterization of the elevated 'zero-maze' as an animal model of anxiety. Psychopharmacology 1994; 116:56-64.
66. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat. Pharmacol Biochem Behav 1986; 24: 525-529.
67. File SE, Zangrossi H, Sanders FL, Mabbutt PS. Raised corticosterone in the rat after exposure to the elevated plus-maze. Psychopharmacology 1994; 113:543-546.
68. Cruz APM, Frei F, Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 1994; 49:171-176.
69. Treit D, Menard J, Royen C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 1993; 44:463-469.
70. File SE, Zangrossi H, Viana M, Graeff FG. Trial 2 in the elevated plus-maze: A different form of fear? Psychopharmacology 1993; 111:491-494.
71. Fernandes C, File SE. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav 1996; 54:31-40.
72. File SE. One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze. Psychopharmacology 1990; 100:281-282.
73. Becker A, Grecksch G. Illumination has no effect on rats' behavior in the elevated plus-maze. Physiol Behav 1996; 59: 1175-1177.
74. Andrews N, File SE. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur J Pharmacol 1993; 235:109-112.
75. File SE, Hyde JRG. Can social interaction be used to measure anxiety? Br J Pharmacol 1978; 62: 19-24.
76. File SE. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 1980; 2: 219-238.
77. File SE. Animal models for predicting clinical efficacy of anxiolytic drugs: Social behaviour. Neuropsychobiology 1985; 13:55-62.
78. File SE, Seth P. A review of 25 years of the social interaction test. Eur J Pharmacol 2003; 463:35-53.
79. File SE. How good is social interaction as a test of anxiety? In: Simon P, Soubrie P, Widlocher D, eds. Selected Models of Anxiety, Depression and Psychosis. Basel: Karger, 1988:151-166.
80. File SE, Hyde JRG. A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquillizers and of stimulants. Pharmacol Biochem Behav 1979; 11:65-69.
81. Vellucci SV, File SE. Chlordiazepoxide loses its anxiolytic action with long-term treatment. Psychopharmacology 1979; 62: 61-65.
82. Fernandes C, Arnot MI, Irvine EE, Bateson AN, Martin IL, File SE. The effect of treatment regimen on the development of tolerance to the sedative and anxiolytic effects of diazepam. Psychopharmacology 1999; 145: 251-259.
83. File SE, Pellow S. The anxiogenic action of Ro 15-1788 is reversed by chronic, but not by acute, treatment with chlordiazepoxide. Brain Res 1984; 310:154-156.
84. Baldwin HA, Johnston AL, File SE. Antagonistic effects of caffeine and yohimbine in animal tests of anxiety. Eur J Pharmacol 1989; 159:211-215.
85. Varlinskaya EI, Spear LP, Spear NE. Acute effects of ethanol on behavior of adolescent rats: Role of social context. Alcohol Clin Exp Res 2001; 25:377-385.
86. Zangrossi H, File SE. Behavioral consequences in animal tests of anxiety and exploration of exposure to cat odor. Brain Res Bull 1992; 29:381-388.
87. Zangrossi H, File SE. Chloriazepoxide reduces the generalized anxiety, but not the direct responses, of rats exposed to cat odor. Pharmacol Biochem Behav 1992; 43:1195-1200.
88. File SE. Chronic exposure to noise modifies the anxiogenic response, but not the hypoactivity, detected on withdrawal from chronic ethanol treatment. Psychopharmacology 1994; 116:369-372.
89. Niesink RJM, Van Ree JM. Short-term isolation increases social interaction of male rats: A parametric analysis. Physiol Behav 1982; 29: 819-825.
90. Johnston AL, File SE. Sex differences in animal tests of anxiety. Physiol Behav 1991; 49:245-250.
91. Ramos A, Berton O, Mormede P, Chaoloff F. A multiple-test study of anxiety-related behaviours in six inbred rat strains. Behav Brain Res 1997; 85:57-69.
92. Kantor S, Anheuer ZE, Bagdy G. High social anxiety and low aggression in fawn-hooded rats. Physiol Behav 2000; 71:551-557.
93. Crawley JN. Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol 2007; 17:448-459.
94. Kask A, Nguyen HP, Pabst R, von Hörsten S. Factors influencing behavior of group-housed male rats in the social interaction test: Focus on cohort removal. Physiol Behav 2001; 74:277-282.
95. Baldwin HA, File SE. Caffeine-induced anxiogenesis: The role of adenosine, benzodiazepine, and noradrenergic receptors. Pharmacol Biochem Behav 1989; 32:181-186.
96. Dunn AJ, File SE. Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Horm Behav 1987; 21:193-202.
97. File SE, Andrews N, Al-Farhan M. Anxiogenic responses of rats on withdrawal from chronic ethanol treatment: Effects of tianeptine. Alcohol Alcohol 1993; 28: 281-286.
98. File SE, Clarke A. Intraventricular ACTH reduces social interaction in male rats. Pharmacol Biochem Behav 1980; 12:711-715.
99. Bolles RC. Learning, motivation, and cognition. In: Estes WK, ed. Handbook of Learning and Cognitive Processes. Hillsdale, NJ: Erlbaum, 1975.
100. De Boer SF, Koolhaas JM. Defensive burying in rodents: Ethology, neurobiology and psychopharmacology. Eur J Pharmacol 2003; 463:145-161.
101. Pinel JPJ, Treit D. Burying as a defensive response in rats. J Comp Physiol Psychol 1978; 92:708-712.
102. Treit D, Pinel JPJ, Fibiger HC. Conditioned defensive burying: A new paradigm for the study of anxiolytic agents. Pharmacol Biochem Behav 1981; 15:619-626.
103. Bondi CO, Barrera G, Lapiz MDS, Bédard T, Mahan A, Morilak DA. Noradrenergic facilitation of shock-probe defensive burying in lateral septum of rats, and modulation by chronic treatment with desipramine. Prog Neuro-Psychopharmacol Biol Psychiatry 2007; 31:482-495.
104. Treit D, Pesold C, Rotzinger S. Dissociating the anti-fear effects of septal and amygdaloid lesions using two pharmacologically validated models of rat anxiety. Behav Neurosci 1993; 107:770-785.
105. Basso AM, Spina M, Rivier J, Vale W, Koob GF. Corticotropin-releasing factor antagonist attenuates the 'anxiogenic-like' effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology (Berl) 1999; 145:21-30.
106. Echevarria DJ, Hernandez A, Diogenes A, Morilak DA. Administration of the galanin antagonist M40 into lateral septum attenuates shock probe defensive burying behavior in rats. Neuropeptides 2005; 39:445-451.
107. Matuszewich L, Karney JJ, Carter SR, Janasik SP, O'Brien JL, Friedman RD. The delayed effects of chronic unpredictable stress on anxiety measures. Physiol Behav 2007; 90:674-681.
108. Pesold C, Treit D. The central and basolateral amygdala differentially mediate the anxiolytic effects of benzodiazepines. Brain Res 1995; 671:213-221.
109. Korte SM, Bouws GA, Koolhaas JM, Bohus B. Neuroendocrine and behavioral responses during conditioned active and passive behavior in the defensive burying/probe avoidance paradigm: Effects of ipsapirone. Physiol Behav 1992; 52:355-361.
110. De Boer SF, Slangen JL, Van der Gugten J. Plasma catecholamine and corticosterone levels during active and passive shock-prod avoidance behavior in rats: Effects of chlordiazepoxide. Physiol Behav 1990; 47:1089-1098.
111. Groenink L, Van der Gugten J, Verdouw PM, Maes RAA, Olivier B. The anxiolytic effects of flesinoxan, a 5-HT1A receptor agonist, are not related to its neuroendocrine effects. Eur J Pharmacol 1995; 280:185-193.
112. Korte SM, Buwalda B, Bouws GA, Koolhaas JM, Maes FW, Bohus B. Conditioned neuroendocrine and cardiovascular stress responsiveness accompanying behavioral passivity and activity in aged and young rats. Physiol Behav 1992; 51:815-822.
113. Menard J, Treit D. Lateral and medial septal lesions reduce anxiety in the plus-maze and probe-burying tests. Physiol Behav 1996; 60:845-853.
114. Degroot A, Kashluba S, Treit D. Septal GABAergic and hippocampal cholinergic systems modulate anxiety in the plus-maze and shock probe tests. Pharmacol Biochem Behav 2001; 69:391-399.
115. Treit D, Pesold C. Septal lesions inhibit fear reactions in two animal models of anxiolytic drug action. Physiol Behav 1990; 47:365-371.
116. Treit D, Terlecki L, Pinel JPJ. Conditioned defensive burying in rodents: Organismic variables. Bull Psychon Soc 1980; 16: 451-454.
117. Pinel JP, Mumby DG, Dastur FN, Pinel JG. Rat (Rattus norvegicus) defensive behavior in total darkness: Risk-assessment function of defensive burying. J Comp Psychol 1994; 108:140-147.
118. Treit D, Lolordo VM, Armstrong DE. The effects of diazepam on 'fear' reactions in rats are modulated by environmental constraints on the rat's defensive repertoire. Pharmacol Biochem Behav 1986; 25: 561-565.
119. Williams JL. Influence of conspecific stress odors and shock controllability on conditioned defensive burying. Anim Learn Behav 1987; 15:333-341.
120. Davis SF, Hazelrigg M, Moore SA, Petty-Zirnstein MK. Defensive burying as a function of food and water deprivation. Bull Psychon Soc 1981; 18:323-327.
121. Roy V, Chapillon P. The positive effects of postnatal handling on defensive burying are more obvious in a situation that enlarges the potential coping responses. Behav Brain Res 2002; 136:67-73.
122. Tsuda A, Tanaka M, Georgiev V, Emoto H. Effects of angiotensin II on behavioral responses of defensive burying paradigm in rats. Pharmacol Biochem Behav 1992; 43: 729-732.
123. Gasparotto OC, Carobrez SG, Bohus BGJ. Effects of LPS on the behavioural stress response of genetically selected aggressive and nonaggressive wild house mice. Behav Brain Res 2007; 183: 52-59.
124. Njung'e K, Handley SL. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991; 38: 63-67.
125. Chotiwat C, Harris RBS. Increased anxiety-like behavior during the post-stress period in mice exposed to repeated restraint stress. Horm Behav 2006; 50:489-495.
126. Engin E, Treit D. The anxiolytic-like effects of allopregnanolone vary as a function of intracerebral microinfusion site: The amygdala, medial prefrontal cortex, or hippocampus. Behav Pharmacol 2007; 18: 461- 470.
127. Fernandes C, McKittrick CR, File SE, McEwen BS. Decreased 5-HT1A and increased 5-HT2A receptor binding after chronic corticosterone associated with a behavioural indication of depression but not anxiety. Psychoneuroendocrinology 1997; 22: 477-491.
128. File SE, Ouagazzal AM, Gonzalez LE, Overstreet DH. Chronic fluoxetine in tests of anxiety in rat lines selectively bred for differential 5-HT1A receptor function. Pharmacol Biochem Behav 1999; 62: 695-701.
129. Saldívar-González A, Gómez C, Martínez-Lomelí I, Arias C. Effect of flumanezil and diazepam on transient actions on defensive burying elicited by the social intercation experience in rats. Pharmacol Biochem Behav 2000; 66: 265-273.
130. Dalley JW, Cardinal RN, Robbins TW. Prefrontal cognitive and executive functions in rodents: Neural and neurochemical substrates. Neurosci Biobehav Rev 2004; 28: 771- 784.
131. Robbins TW. The 5-choice serial reaction time task: Behavioural pharmacology and functional neurochemistry. Psychopharmacology 2002; 163: 362-380.
132. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997; 8: 523-532.
133. Porsolt RD, Brossard G, Hautbois C, Roux S. Rodent models of depression: forced swimming and tail suspension behavioral despair tests in rats and mice. In: Crawley JN, Gerfen CR, Rogawski MA, Sibley DR, Skolnick P, Wray S, eds. Current Protocols in Neuroscience. New York, NY: John Wiley & Sons, 2001: 8.10A.1- 8.10A.10.
134. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005; 29: 547-569.
135. Drugan RC. Rodent models of depression: Learned helplessness using a triadic design in rats. In: Crawley JN, Gerfen CR, Rogawski MA, Sibley DR, Skolnick P, Wray S, eds. Current Protocols in Neuroscience. New York, NY: John Wiley & Sons, 2001: 8.10B.1-8.10B.12.
136. Maier SF. Learned helplessness and animal models of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 1984; 8: 435-446.
137. Maier SF, Seligman MEP. Learned helplessness: Theory and evidence. J Exp Psychol Gen 1976; 105: 3-46.
138. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987; 93: 358-364.
139. Davis M. Fear-potentiated startle in rats. In: Crawley JN, Gerfen CR, Rogawski MA, Sibley DR, Skolnick P, Wray S, eds. Current Protocols in Neuroscience. New York, NY: John Wiley & Sons, 2001: 8.11A.1- 8.11A.11.
140. File SE. Animal models of different anxiety states. Adv Biochem Psychopharmacol 1995; 48: 93-113.
141. Handley SL, McBlane JW. 5HT drugs in animal models of anxiety. Psychopharmacology 1993; 112: 13- 20.
142. Millan MJ, Brocco M. The Vogel conflict test: Procedural aspects, γ-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 2003; 463: 67-96.
143. Davis M, Falls WA, Campeau S, Kim M. Fear-potentiated startle: A neural and pharmacological analysis. Behav Brain Res 1993; 58: 175-198.
144. Sanders SK, Morzorati SL, Shekhar A. Priming of experimental anxiety by repeated subthreshold GABA blockade in the rat amygdala. Brain Res 1995; 699: 250-259.
145. Brudzynski SM. Principles of rat communication: Quantitative parameters of ultrasonic calls in rats. Behav Genet 2005; 35: 85-92.
146. Jelen P, Soltysik S, Zagrodska J. 22-kHz Ultrasonic vocalization in rats as an index of anxiety but not fear: Behavioral and pharmacological modulation of affective state. Behav Brain Res 2003; 141: 63-72.
147. Litvin Y, Blanchard DC, Blanchard RJ. Rat 22 kHz ultrasonic vocalizations as alarm cries. Behav Brain Res 2007; 182: 166-172.